Online citations, reference lists, and bibliographies.
← Back to Search

Effect Of Botulinum Toxin Concentration On Reduction In Sweating: A Randomized, Double-blind Study.

A. Rystedt, M. Karlqvist, M. Bertilsson, H. Naver, C. Swartling
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Dose-response studies of botulinum toxin for reduction of sweating are sparse in the literature. The aim of this study was to determine the most appropriate concentrations of Botox®, Dysport®, Xeomin® and NeuroBloc®, respectively, in order to achieve the greatest reduction in sweating, thus reducing the costs and increasing the safety of treatment. Four concentrations of each product were investigated. Intradermal injections of all products and concentrations were applied to the backs of 20 consenting subjects, in a randomized, double-blind manner. Areas of anhidrotic and hypohidrotic skin were measured with an iodine-starch test after 4, 8 and 12 weeks, respectively. Optimal concentrations were found to be 25 U/ml for Botox and Xeomin, approximately 100 U/ml for Dysport, and 50 U/ml for NeuroBloc. When comparing the mean anhidrotic area per unit for 100 U/ml of each product, the calculated dose conversion ratios were 1:1.6:1.2:1.3 (Botox:Dysport:Xeomin:NeuroBloc). If, instead, the optimal concentration for each product was compared, the dose conversion ratios were 1:4.8:1.3:2.2. Thus, it is crucial to consider botulinum toxin concentration in a treatment regimen.
This paper references
10.1016/S0165-1838(97)00014-3
Altered response in cutaneous sympathetic outflow to mental and thermal stimuli in primary palmoplantar hyperhidrosis.
S. Iwase (1997)
10.1046/J.1523-1747.2003.12620.X
Botulinum toxin type B blocks sudomotor function effectively: a 6 month follow up.
F. Birklein (2003)
10.1136/jnnp.64.1.6
A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox®in the treatment of cervical dystonia
T. Odergren (1998)
10.1046/J.1524-4725.2003.29017.X
Comparison of Botulinum Toxin Types A And B: A Bilateral and Double‐Blind Randomized Evaluation in the Treatment of Canthal Rhytides
S. Matarasso (2003)
10.1053/SDER.2001.24421
Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology.
J. E. Callaway (2002)
10.1212/WNL.53.7.1431
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
A. Brashear (1999)
10.1002/MDS.870120627
DYSBOT: A single‐blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1
C. Sampaio (1997)
10.1111/j.1468-1331.2006.01439.x
Immunological aspects of Botox®, Dysport® and MyoblocTM/NeuroBloc®
D. Dressler (2006)
10.1007/BF01652699
Ein neues Verfahren zu der klinischen Untersuchung der Schweißabsonderung
Victor Minor (2005)
10.1007/BF00941758
Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm
Zita Nüβgens (2004)
10.1016/J.TOXICON.2008.04.128
Anhidrotic effect of intradermal injections of botulinum toxin—A comparison of different products and concentrations
R. Alma (2008)
10.1002/mds.22336
Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double‐blind study
G. Kranz (2009)
10.1016/j.toxicon.2009.02.003
Discussion of unique properties of botulinum toxins.
Alberto Albanese (2009)
10.1111/j.1365-2133.2010.10085.x
Long‐term efficacy and respective potencies of botulinum toxin A and B: a randomized, double‐blind study
G. Kranz (2011)
10.1136/jnnp.72.4.459
Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia
D. Ranoux (2002)
10.1212/wnl.53.7.1431
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
M. Brin (1999)
Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm
Zita Niiligens (1997)
10.1007/s00415-002-0929-4
Botulinum toxin type B for treatment of axillar hyperhidrosis
D. Dressler (2002)
Ein neues verfahren zu der klinischen unter - suchung der schweissabsonderung
V Minor (1927)
10.1185/03007990903028203
Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment?
K. Wohlfarth (2009)
Clinical bioequivalence of the current commercial preparations of botulinum toxin
F Durif (1995)
10.1007/PL00004951
Botulinum A toxins: units versus units
K. Wohlfarth (1997)
10.2340/00015555-0490
Equipotent concentrations of Botox and Dysport in the treatment of palmar hyperhidrosis.
A. Rystedt (2008)
10.2165/00003495-200767050-00003
Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN®) in Focal Dystonia
W. Jost (2012)



This paper is referenced by
10.2340/00015555-2665
Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis.
S. Motegi (2017)
10.2147/BTT.S65603
Botulinum toxin type A products are not interchangeable: a review of the evidence
M. Brin (2014)
10.1007/s00403-014-1449-7
Efficacy of botulinum toxin type B for the treatment of primary palmar hyperhidrosis: a prospective, open, single-blind, multi-centre study
M. Basciani (2014)
10.2340/00015555-2755
Hyperhidrosis Substantially Reduces Quality of Life in Children: A Retrospective Study Describing Symptoms, Consequences and Treatment with Botulinum Toxin.
S. Mirkovic (2018)
10.1007/s10286-015-0278-x
Treatment of compensatory hyperhidrosis after sympathectomy with botulinum toxin and anticholinergics
Anna Karlsson-Groth (2015)
10.29245/2572.942x/2016/4.1037
Hyperhidrosis - an unknown widespread "silent" disorder
Carl Swartling (2016)
10.1007/s40257-020-00537-9
Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study
Ø. Grimstad (2020)
10.1007/s00702-019-02060-6
“New methods of assessing autonomic disorders in Parkinson disease patients: skin-galvanic reaction”
J. Dutkiewicz (2019)
10.1016/j.det.2014.06.012
Botulinum neurotoxin treatment of palmar and plantar hyperhidrosis.
Tessa Weinberg (2014)
10.1038/s41467-017-00064-y
Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors
Liang Tao (2017)
10.1371/journal.pone.0191043
Assessing adverse effects of intra-articular botulinum toxin A in healthy Beagle dogs: A placebo-controlled, blinded, randomized trial
H. Heikkilä (2018)
10.1371/journal.pbio.3000618
Characterization of a membrane binding loop leads to engineering botulinum neurotoxin B with improved therapeutic efficacy
L. Yin (2020)
10.1111/1346-8138.15029
Postmenopausal craniofacial hyperhidrosis treated with botulinum toxin type B
Philip Cabreus (2019)
10.1097/WNF.0000000000000101
A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1: 3 and 1 1.7 in the Treatment of Cervical Dystonia A Double-Blind, Randomized, Crossover Trial
A. Rystedt (2015)
Semantic Scholar Logo Some data provided by SemanticScholar